Bone resorption in syndromes of the Ras/MAPK pathway

Clinical Genetics

Volumn 80, Issue 6, 2011, Pages 566-573

  Stevenson, Da ^a,b   Schwarz, El ^c   Carey, Jc ^a,b   Viskochil, Dh ^a,b   Hanson, H ^a   Bauer, S ^a   Cindy Weng, H Y ^a   Greene, T ^a   Reinker, K ^d   Swensen, J ^c   Chan, Rj ^e   Yang, F C ^e   Senbanjo, L ^e   Yang, Z ^e   Mao, R ^c   Pasquali, M ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bone; Cardiofaciocutaneous syndrome; Costello syndrome; Noonan syndrome; Pyridinium

Indexed keywords

B RAF KINASE; DEOXYPYRIDINOLINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PYRIDINOLINE; RAS PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CARDIOFACIOCUTANEOUS SYNDROME; CHILD; COLLAGEN DEGRADATION; CONTROLLED STUDY; COSTELLO SYNDROME; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; MULTIPLE MALFORMATION SYNDROME; NOONAN SYNDROME; OSTEOLYSIS; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIGNAL TRANSDUCTION;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; COLLAGEN; COSTELLO SYNDROME; DNA MUTATIONAL ANALYSIS; ECTODERMAL DYSPLASIA; FACIES; FAILURE TO THRIVE; FEMALE; GENETIC TESTING; HEART DEFECTS, CONGENITAL; HUMANS; HYDROLYSIS; MALE; MAP KINASE SIGNALING SYSTEM; NOONAN SYNDROME; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 80054917169     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2010.01619.x     Document Type: Article

References (54)

1. Tartaglia M, Pennacchio LA, Zhao C et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007: 39: 75-79.
2. Tartaglia M, Mehler EL, Goldberg R et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001: 29: 465-468.
3. Pandit B, Sarkozy, A, Pennacchio LA et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 2007: 39: 1007-1012.
4. Cirstea IC, Kutsche K, Dvorsky R et al. A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet 2010: 42: 27-29.
5. Cordeddu V, Di Schiavi E, Pennacchio LA et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet 2009: 41: 1022-1026.
6. Schubbert S, Zenker M, Rowe SL et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006: 38: 331-336.
7. Rodriguez-Viciana P, Tetsu O, Tidyman WE et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006: 311: 1287-1290.
8. Niihori T, Aoki Y, Narumi Y et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006: 38: 294-296.
9. Aoki Y, Niihori T, Kawame H et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005: 37: 1038-1040.
10. Yang FC, Chen S, Robling AG et al. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1 - haploinsufficient osteoclast functions. J Clin Invest 2006: 116: 2880-2891.
11. Yu X, Chen S, Potter OL et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 2005: 36: 793-802.
12. Wu X, Estwick SA, Chen S et al. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet 2006: 15: 2837-2845.
13. Elefteriou F, Benson MD, Sowa H et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 2006: 4: 441-451.
14. Gutmann DH, Aylsworth A, Carey JC et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997: 278: 51-57.
15. Crawford AH, Schorry EK. Neurofibromatosis in children; the role of the orthopaedist. J Am Acad Orthop Surg 1999: 7: 217-230.
16. Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1728 patients. Am J Med Genet 1997: 70: 138-143.
17. Stevenson DA, Birch PH, Friedman JM et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 1999: 84: 413-419.
18. Vitale MG, Guha A, Skaggs DL. Orthopaedic manifestations of neurofibromatosis in children: an update. Clin Orthop Relat Res 2002: 401: 107-118.
19. Illes T, Halmai V, de Jonge T et al. Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 2001: 12: 823-827.
20. Yilmaz K, Ozmen M, Bora Goksan S et al. Bone mineral density in children with neurofibromatosis 1. Acta Paediatr 2007: 96: 1220-1222.
21. Kuorilehto T, Pöyhönen M, Bloigu R et al. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 2005: 16: 928-1396.
22. Lammert M, Kappler M, Mautner VF et al. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 2005: 16: 1161-1166.
23. Stevenson DA, Moyer-Mileur LJ, Murray M et al. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 2007: 150: 83-88.
24. Dulai S, Briody J, Schindeler A et al. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 2007: 27: 472-475.
25. Stevenson DA, Moyer-Mileur LJ, Carey JC et al. Case-control study of the muscular compartments and osseous strength in neurofibromatosis type 1 using peripheral quantitative computed tomography. J Musculoskelet Neuron Interact 2005: 5: 145-149.
26. Caffarelli C, Gonnelli S, Tanzilli L et al. Quantitative ultrasound and dual energy x-ray absorptiometry in children and adolescents with neurofibromatosis of type 1. J Clin Densitom 2010: 13: 77-83.
27. Tucker T, Schnabel C, Hartmann M et al. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 2009: 46: 259-265.
28. Seitz S, Schnabel C, Busse B et al. High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 2010: 21: 119-127.
29. Brunetti-Pierri N, Doty SB, Hicks J et al. Generalized metabolic bone disease in Neurofibromatosis type 1. Mol Genet Metab 2008: 94: 105-111.
30. Sharland M, Burch M, McKenna WM et al. A clinical study of Noonan syndrome. Arch Dis Child 1992: 67: 178-183.
31. Nora JJ, Nora AH, Sinha AK et al. The Ullich-Noonan syndrome (Turner phenotype). Am J Dis Child 1974: 127: 48-55.
32. Allanson JE. Noonan syndrome. J Med Genet 1987: 24: 9-13.
33. Lee CK, Chang BS, Hong YM et al. Spinal deformities in Noonan syndrome: a clinical review of sixty cases. J Bone Joint Surg Am 2001: 83-A: 1495-1502.
34. Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med Genet 2008: 45: 249-254.
35. White SM, Graham JM Jr, Kerr B et al. The adult phenotype in Costello syndrome. Am J Med Genet A 2005: 136: 128-135.
36. Yassir WK, Grottkau BE, Goldberg MJ. Costello syndrome: orthopaedic manifestations and functional health. J Pediatr Orthop 2003: 23: 94-98.
37. Eastell R, Blumsohn A. The value of biochemical markers of bone turnover in osteoporosis. J Rheum 1997: 24: 1215-1217.
38. McLaren AM, Hordon LD, Bird HA et al. Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture. Ann Rheum Dis 1992: 51: 648-651.
39. Rosen HN, Dresner-Pollak R, Moses AC et al. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 1994: 54: 26-29.
40. Delmas PD, Schlemmer A, Gineyts E et al. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991: 6: 639-644.
41. Robins SP, Black D, Paterson CR et al. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991: 21: 310-315.
42. Pasquali M, Still MJ, Vales T et al. Abnormal formation of collagen cross-links in skin fibroblasts cultured from patients with Ehlers-Danlos Syndrome Type VI. Proc Assoc Am Physicians 1997: 109: 33-41.
43. Pasquali M, Still MJ, Dembure PP et al. Pyridinium cross-links in heritable disorders of collagen. Am J Hum Genet 1995: 57: 1508-1510.
44. Uebelhart D, Gineyts E, Chapuy MC et al. Urinary excretion of pyridinium crosslinks: a new marker of bone resporption in metabolic bone disease. Bone Miner 1990: 8: 87-96.
45. Eyre DR, Koob TJ, Van Ness KP. Quantification of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 1984: 137: 380-388.
46. Bettica P, Moro L, Robins SP et al. Bone-resorption markers galactosyl hydroxylysine, pyridinium crosslinks, and hydroxyproline compared. Clin Chem 1992: 38: 2131-2318.
47. Stevenson DA, Schwarz EL, Viskochil DH et al. Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res 2008: 63: 697-701.
48. Heervä E, Alanne MH, Peltonen S et al. Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 2010: 47: 583-590.
49. Rockett HR, Breitenbach M, Frazier AL et al. Validation of a youth/adolescent food frequency questionnaire. Prev Med 1997: 26: 808-816.
50. Ainsworth BE, Haskell WL, Leon AS et al. Compendium of physical activities: classification of energy cost of human physical activities. Med Sci Sports Exerc 1993: 25: 71-80.
51. Bailey RL, Dodd KW, Goldman JA et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010: 140: 817-822.
52. Stevenson DA, Zhou H, Ashrafi S et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 2006: 79: 143-148.
53. Kolanczyk M, Kossler N, Kühnisch J et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 2007: 16: 874-886.
54. Branca F, Spagnoli A, Cianfarani S et al. Urinary excretion of pyridinium crosslinks in short children treated with growth hormone. J Pediatr Endocrinol Metab 2002: 15: 27-34.